Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The National Institutes of Health has encouraged research examining effects of BPA, yet evidence in humans evaluating the effects of BPA on insulin and glucose concentrations remains exclusively associative in nature. Thus, the primary purpose of this study is to determine whether an acute oral ingestion of BPA impacts insulin and glucose concentrations, and other endocrine factors (Pro-insulin, C-Peptide, Estrogen, triglycerides). Findings from this pilot study will inform public health recommendations for food packaging and provide much needed experimental evidence as to whether BPA poses any public health risk.
The prevalence of diabetes is well established affecting >29 million Americans with 90-95% of these individuals diagnosed with type 2 diabetes. The etiology of type 2 diabetes is not fully understood, but clearly diet, physical activity, and genetics play roles. Emerging data suggests a novel hypothesis that synthetic non-persistent endocrine disruptors used in a variety of common consumer goods, including the industry-produced chemical bisphenol A (BPA) play a pivotal role in type 2 diabetes and obesity rates. In support of this hypothesis, National Health and Nutrition Examination Survey (NHANES), Nurses' Health Study II (NHSII), and other cross-sectional data have shown associations between urinary BPA concentrations and type-2 diabetes, pre-diabetes, insulin resistance, and hemoglobin A1c. The National Institutes of Health has encouraged research examining effects of BPA, yet evidence in humans evaluating the effects of BPA on insulin and glucose concentrations remains exclusively associative in nature. Thus, the primary purpose of this study is to determine whether an acute oral ingestion of BPA impacts insulin and glucose concentrations, and other endocrine factors (Pro-insulin, C-Peptide, Estrogen, triglycerides) in the pathogenesis of Type 2 diabetes and cardiovascular disease. Findings from this pilot study will inform public health recommendations for food packaging and provide much needed experimental evidence as to whether BPA poses any public health risk.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Participants consume Vanilla Wafer cookie |
|
| BPA 4 ug/kg BW | Experimental | Participants consume 4 ug/kg BW of BPA on a Vanilla Wafer Cookie |
|
| BPA 50 ug/kg BW | Experimental | Participants consume 50 ug/kg BW of BPA on a Vanilla Wafer Cookie |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo | Other | Ingestion of Placebo |
| |
| BPA 4 ug/kg BW |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline Glucose at 180 Minutes | Glucose concentrations will be assessed before and in response to a 75 gram Oral Glucose Tolerance Test | 9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180 |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline Insulin at 180 Minutes | Insulin concentrations will be assessed before and in response to a 75 gram Oral Glucose Tolerance Test | 9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180 |
| Change From Baseline Estrogen at 180 Minutes |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Todd Hagobian, PhD | California Polytechnic State University-San Luis Obispo | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| California Polytechnic State University | San Luis Obispo | California | 93405 | United States |
No plan to share data in this pilot study
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Double-blinded study; Study statistician computer generated randomization
| Other |
Oral BPA ingestion of 4 ug/kg BW |
|
| BPA 50 ug/kg BW | Other | Oral BPA ingestion of 50 ug/kg BW |
|
Estrogen concentrations will be assessed before and in response to a 75 gram Oral Glucose Tolerance Test |
| 9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180 |
| Change From Baseline C-Peptde at 180 Minutes | C-Peptide concentrations will be assessed before and in response to a 75 gram Oral Glucose Tolerance Test | 9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180 |
| Change From Baseline Pro-Insulin at 180 Minutes | Pro-Insulin concentrations will be assessed before and in response to a 75 gram Oral Glucose Tolerance Test | 9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180 |
| Change From Baseline Triglycerides at 180 Minutes | Triglyceride concentrations will be assessed before and in response to a 75 gram Oral Glucose Tolerance Test | 9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180 |